Form 4: VYNE Therapeutics CEO David Domzalski Reports Stock Transaction
SEC Form 4 Filing
David Domzalski, CEO of VYNE Therapeutics, reports disposition of shares to cover tax obligations related to vesting of restricted stock units.
Summary
- On July 1, 2024, David Domzalski, the President and CEO of VYNE Therapeutics Inc., reported a transaction involving the disposition of 935 shares of common stock.
- The shares were disposed of to satisfy tax withholding requirements related to the vesting of restricted stock units.
- The price per share was $1.92.
- Following the transaction, Domzalski directly owns 497,654 shares of VYNE Therapeutics Inc.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing a stock transaction for tax purposes, which is neither particularly positive nor negative.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track executive compensation and potential alignment with shareholder interests.
Key Dates
| Date | Description |
|---|---|
| 07/01/2024 | Date of stock transaction |
| 07/03/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.